Given Imaging
This article was originally published in The Gray Sheet
Executive Summary
Proposed initial public offering likely will help support commercialization of the Israeli firm's Given swallowable camera microcapsule. Wireless endoscopy diagnostic imaging system gained 510(k) clearance Aug. 1 as an adjunctive tool to visualize the inside of the small intestines to detect polyps, cancer or causes of bleeding (1"The Gray Sheet" Aug. 6, 2001, In Brief). The number of shares and aggregate value of the offering, anticipated to occur by year-end, have not yet been determined. The firm is preparing to file a registration statement with the SEC
You may also be interested in...
Given camera pill
Given Imaging's swallowable capsule for visualizing the inside of the small intestine to detect polyps, cancer or causes of bleeding gains FDA market go-ahead Aug. 1 via agency's 510(k) de novo process. The diagnostic imaging system is intended for use in conjunction with other endoscopic or radiological examinations. The capsule incorporates a small camera, lights, image transmitter and eight-hour battery (1"The Gray Sheet" July 30, 2001, p. 14)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.